5 Our three late-stage clinical assets target leading causes of vision loss *KSI-101 initial addressable population in MESI. Kodiak Data on File and shared Investor R&D Day July 2025. 1. Fleckenstein M, et al. JAMA. 2024;331(2):147–157. 2. Boopathiraj N, et al. Mayo Clinic Proceedings: Innovations, Quality & Outcomes , 2024; 8, 364-374. 3. Market Scope. 2024 Retinal Pharmaceuticals Market Report. 4. Song, P., et al. (2019). Journal of Global Health . https://doi.org/10.7189/jogh.09.010427. 5. Kalva, P et al. Baylor University Medical Center Proceedings , 36 (3), 335–340. 6. The Diabetes Atlas, Accessed May 2026. 7. James H.B. et al. Survey of Ophthalmology, 2022;67(4): 1244-1251. 8. Roche epidemiology data 2025. 9. WHO, 2019, World Report on Vision Executive Summary. ABC: antibody biopolymer conjugate; MESI: macular edema secondary to inflammation; AMD: age-related macular degeneration; RVO: retinal vein occlusion DME: diabetic macular edema DR: diabetic retinopathy Estimated global prevalence DR DME RVO wAMD ~32M 6,7 ~28M 4 ~20M 1,2 MESI ~150k* (U.S.) ~1.8M U.S. 3 ~1.0M U.S. 5 ~3.2M U.S. 8 ~9.6M U.S. 8 ~146M 9 KSI-101 Phase 3 Anti-IL-6, VEGF Trap Intravitreal Protein MESI Zenkuda Phase 3 Anti-VEGF Intravitreal ABC ® wAMD, DR, RVO Phase 3 Anti-IL-6, VEGF Trap Intravitreal ABC ® KSI-501 wAMD, DME